NASDAQ · KZIA
Kazia Therapeutics Ltd ADR
$8.72+$0.39 (+4.68%)
Kazia Therapeutics Ltd ADR’s quoted price sits in the lower half of its reported 52-week range, 49.89% below the high.
Loading market information…
AMEX · CLDI · USD
Stock price, earnings
Quote as of Oct 29, 2026, 07:59 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Calidi Biotherapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 97.49% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Calidi Biotherapeutics, Inc.’s next earnings report is currently expected on Nov 17, 2026. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Calidi Biotherapeutics, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Calidi Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on immuno-oncology, dedicated to developing advanced immunotherapies for various cancers. The company's innovative approach centers on utilizing powerful, allogeneic (donor-derived) stem cells as specialized carriers for anti-tumor agents. This technology is being advanced to address a range of oncological conditions, including aggressive brain tumors (high-grade gliomas) and other solid malignancies. Calidi's proprietary cell-based delivery systems are expertly designed to safeguard, amplify, and boost the therapeutic effects of oncolytic viruses. This strategic delivery method aims to achieve superior treatment efficacy and enhance patient safety. The company's clinical pipeline features two primary candidates: NeuroNova, which employs allogeneic neural stem cells loaded with an oncolytic adenovirus specifically for the treatment of high-grade gliomas; and SuperNova, which utilizes allogeneic adipose-derived mesenchymal stem cells to deliver the tumor-selective CAL1 oncolytic vaccinia virus for advanced metastatic solid tumors. Established in 2014, Calidi Biotherapeutics operates out of San Diego, California.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:56 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| $0.00 |
| Q3 2024 | Nov 12, 2024 | -$124.85+23.99% vs estimate | $0.00 |
|---|
THE ANALYST VIEW
2 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$8.72+$0.39 (+4.68%)
Kazia Therapeutics Ltd ADR’s quoted price sits in the lower half of its reported 52-week range, 49.89% below the high.
$0.37-$0.01 (-1.55%)
Soligenix, Inc.’s quoted price sits in the lower half of its reported 52-week range, 78.28% below the high.
$4.77+$0.26 (+5.76%)
CNS Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 54.74% below the high.
$3.21+$0.17 (+5.59%)
Qualigen Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 63.56% below the high.
$2.12+$0.02 (+0.95%)
Xenetic Biosciences, Inc.’s quoted price sits in the lower half of its reported 52-week range, 57.09% below the high.
$0.95+$0.10 (+11.87%)
60 Degrees Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 89.01% below the high.
$2.34-$0.30 (-11.36%)
Titan Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 84.55% below the high.
$5.85-$0.21 (-3.47%)
Clearmind Medicine Inc.’s quoted price sits in the lower half of its reported 52-week range, 99.81% below the high.
